EFEPA Offices

Epilepsy Foundation Eastern Pennsylvania

919 Walnut Street, Suite 700

Philadelphia, PA 19107-5237

Main Number: (215) 629-5003

PA Toll Free: (800) 887-7165

FAX: (215) 629-4997
efepa@efepa.org


Wyoming Valley Office
71 N. Franklin St
Kirby Health Center
Wilkes Barre, PA 18701
epilepsywv@efepa.org
(570) 592-1150

Lehigh Valley
Allentown, PA
lv@efepa.org
(610) 737-0613

Lancaster County
Lancaster, PA
kmichnya@efepa.org
(215) 629-5003 x104
Hours: 8:30 am - 4:30 pm, Monday - Friday

Resources for Women

The EFEPA holds women’s conference…………. (link to women’s conference)
Exchange Presentation
Childcare
Bone Health


Epilepsy Treatment

16 March, 2016

Positive Phase 3 Pivotal Study Results for Epiodiolex (cannabidiol) from GW Pharmaceuticals

By | 2017-03-30T13:16:05+00:00 March 16th, 2016|Education, Epilepsy Medication, Media, Uncategorized|0 Comments

London, UK; 14 March 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: “GWP,” “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces the positive results of the first pivotal Phase 3 study of its investigational medicine Epidiolex® (cannabidiol or CBD) for [...]

11 January, 2012

ONFI (clobazam) Tablets now Available in the U.S. at Pharmacies

By | 2017-03-30T13:16:08+00:00 January 11th, 2012|Epilepsy Medication, Treatment, Uncategorized|0 Comments

DEERFIELD, Ill.--(BUSINESS WIRE)--Lundbeck announced today that ONFI Tablets are now available for prescribing in the United States. The FDA recently approved ONFI for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients two years and older.1 ONFI is an oral anti-epileptic drug (AED) of the benzodiazepine class, and is a 1,5 benzodiazepine.1 ONFI [...]